Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 10/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.67 |
| ▸ | DHODH | Q02127 | 1/20 | 0.66 |
| ▸ | GFER | P55789 | 1/20 | 0.65 |
| ▸ | TACR2 | P21452 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6969107 | 0.98 | TACR3 (0.71) | TACR3CYP3A4KDM4ELMNASMN1; SMN2 | |
| SCHEMBL19508774 | 0.92 | CYP3A4 (0.73) | TACR3CYP3A4KDM4ESMN1; SMN2MEN1 | |
| SCHEMBL17689194 | 0.86 | CYP3A4 (0.77) | CYP3A4KDM4ELMNASMN1; SMN2MEN1 | |
| SCHEMBL14133006 | 0.85 | TACR3 (0.72) | TACR3CYP3A4KDM4ELMNASMN1; SMN2 | |
| SCHEMBL28844474 | 0.84 | TACR3 (0.79) | TACR3CYP3A4KDM4ELMNASMN1; SMN2 | |
| SCHEMBL6450086 | 0.84 | TACR3 (1.00) | TACR3CYP3A4KDM4ELMNASMN1; SMN2 | |
| SCHEMBL23722846 | 0.84 | TACR3 (0.70) | TACR3CYP3A4KDM4ELMNASMN1; SMN2 | |
| SCHEMBL14970875 | 0.84 | CYP3A4 (1.00) | TACR3CYP3A4KDM4ELMNASMN1; SMN2 | |
| SCHEMBL6209856 | 0.83 | KDM4E (0.76) | TACR3CYP3A4KDM4ELMNASMN1; SMN2 | |
| SCHEMBL4471933 | 0.82 | TACR3 (1.00) | TACR3CYP3A4KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170152260-A1 | STAT3 INHIBITOR | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-06-01 | — | — | US | disclosed |
| WO-2007008657-A2 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170152260-A1 | STAT3 INHIBITOR | STAT3, STAT1, STAT4 | TACR3 3797/4885CYP3A4 3978/4885KDM4E 3388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.